Home LiteratureArticle Details
PMID: 22239576 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't Review

From the prodrome to chronic schizophrenia: the neurobiology underlying psychotic symptoms and cognitive impairments.

Current pharmaceutical design ·Vol. 18 ·No. 4 ·2012-00-00 ·Pages 459-65

Howes OD, Fusar-Poli P, Bloomfield M, Selvaraj S, McGuire P

Abstract

Schizophrenia is a chronic psychotic disorder that remains a considerable cause of global disease burden. Cognitive impairments are common and contribute significantly to the morbidity of the disorder. Over the last two decades or so molecular imaging studies have refined understanding of the pathophysiology underlying the development of psychosis and cognitive impairments. Firstly they have consistently implicated presynaptic dopaminergic dysfunction in the disorder, finding that dopamine synthesis capacity, dopamine release and baseline dopamine levels are increased in the illness. Secondly recent findings show that dopamine synthesis capacity is elevated in those that go on to develop psychosis in the following year, but not in those that do not, and appears to increase further with the development of psychosis. Thirdly evidence links greater dopamine synthesis capacity to poorer cognitive performance and altered frontal cortical function measured using functional imaging during cognitive tasks. Finally they have provided data on the nature of other neurofunctional alterations in the disorder, in particular in the serotonergic system and neuroinflammation. We review these findings and discuss their implications for understanding the neurobiology of psychosis and cognitive impairments in schizophrenia.

MeSH Terms
Chronic Disease Cognition Disorders/diagnosis,metabolism,psychology Dopamine/metabolism Early Diagnosis Humans Neuroimaging/methods Psychotic Disorders/diagnosis,metabolism,psychology Schizophrenia/diagnosis,etiology,metabolism Serotonin/metabolism
Chemicals
Serotonin Dopamine
Authors & Affiliations
5 authors, click to expand affiliations / ORCID
Howes O D
Psychiatric Imaging Group Cyclotron Building Hammersmith Hospital, London W12 0NN, UK. oliver.howes@csc.mrc.ac.uk
Fusar-Poli P
Bloomfield M
Selvaraj S
McGuire P
References (95)
95 references, click to expand
  1. Altered relationship between hippocampal glutamate levels and striatal dopamine function in subjects at ultra high risk of psychosis.
    Biol Psychiatry. 2010 Oct 1;68(7):599-602 PMID: 20638047
  2. Imaging changes in glutamate transmission in vivo with the metabotropic glutamate receptor 5 tracer [11C] ABP688 and N-acetylcysteine challenge.
    Biol Psychiatry. 2011 May 1;69(9):822-4 PMID: 21288506
  3. Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study.
    Lancet. 1997 May 17;349(9063):1436-42 PMID: 9164317
  4. Decreased 5-HT1A receptor binding in amygdala of schizophrenia.
    Biol Psychiatry. 2004 Mar 1;55(5):439-44 PMID: 15023569
  5. Increase in HLA-DR immunoreactive microglia in frontal and temporal cortex of chronic schizophrenics.
    J Neuropathol Exp Neurol. 2000 Feb;59(2):137-50 PMID: 10749103
  6. Schizophrenia: manifestations, incidence and course in different cultures. A World Health Organization ten-country study.
    Psychol Med Monogr Suppl. 1992;20:1-97 PMID: 1565705
  7. Provocative tests with psychostimulant drugs in schizophrenia.
    Psychopharmacology (Berl). 1987;91(4):415-33 PMID: 2884687
  8. The global costs of schizophrenia.
    Schizophr Bull. 2004;30(2):279-93 PMID: 15279046
  9. 'Truman' signs and vulnerability to psychosis.
    Br J Psychiatry. 2008 Aug;193(2):168 PMID: 18670010
  10. Epidemiology of schizophrenia: the global burden of disease and disability.
    Eur Arch Psychiatry Clin Neurosci. 2000;250(6):274-85 PMID: 11153962
  11. The role of dopamine for the pathophysiology of schizophrenia.
    Int Rev Psychiatry. 2007 Aug;19(4):337-45 PMID: 17671867
  12. Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: evidence from a novel positron emission tomography method.
    Proc Natl Acad Sci U S A. 1997 Mar 18;94(6):2569-74 PMID: 9122236
  13. Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs.
    Science. 1976 Apr 30;192(4238):481-3 PMID: 3854
  14. Neural correlates of executive function and working memory in the 'at-risk mental state'.
    Br J Psychiatry. 2009 Jan;194(1):25-33 PMID: 19118321
  15. Antipsychotic drug actions: a clue to the neuropathology of schizophrenia?
    Fed Proc. 1973 Feb;32(2):200-5 PMID: 4348519
  16. 3,4-Dihydroxyphenylalanine and 5-hydroxytryptophan as reserpine antagonists.
    Nature. 1957 Nov 30;180(4596):1200 PMID: 13483658
  17. The role of serotonin in the pathophysiology and treatment of schizophrenia.
    J Neuropsychiatry Clin Neurosci. 1997 Winter;9(1):1-17 PMID: 9017523
  18. Striatal amphetamine-induced dopamine release in patients with schizotypal personality disorder studied with single photon emission computed tomography and [123I]iodobenzamide.
    Biol Psychiatry. 2004 May 15;55(10):1001-6 PMID: 15121484
  19. Glutamate receptor dysfunction and schizophrenia.
    Arch Gen Psychiatry. 1995 Dec;52(12):998-1007 PMID: 7492260
  20. Serotonin 5-HT2 receptors in schizophrenic patients studied by positron emission tomography.
    Life Sci. 2000;66(25):2455-64 PMID: 10894088
  21. Evidence for activation of microglia in patients with psychiatric illnesses.
    Neurosci Lett. 1999 Aug 20;271(2):126-8 PMID: 10477118
  22. Classification of schizophrenic patients and healthy controls using [18F] fluorodopa PET imaging.
    Schizophr Res. 2008 Dec;106(2-3):148-55 PMID: 18849151
  23. Course and long-term treatment of schizophrenic psychoses.
    Pharmacopsychiatry. 2004 Nov;37 Suppl 2:126-35 PMID: 15546064
  24. Microglia activation in recent-onset schizophrenia: a quantitative (R)-[11C]PK11195 positron emission tomography study.
    Biol Psychiatry. 2008 Nov 1;64(9):820-2 PMID: 18534557
  25. Antipsychotic drug doses and neuroleptic/dopamine receptors.
    Nature. 1976 Jun 24;261(5562):717-9 PMID: 945467
  26. Transient and selective overexpression of dopamine D2 receptors in the striatum causes persistent abnormalities in prefrontal cortex functioning.
    Neuron. 2006 Feb 16;49(4):603-15 PMID: 16476668
  27. Working memory impairments in schizophrenia: a meta-analysis.
    J Abnorm Psychol. 2005 Nov;114(4):599-611 PMID: 16351383
  28. Psychosis as a state of aberrant salience: a framework linking biology, phenomenology, and pharmacology in schizophrenia.
    Am J Psychiatry. 2003 Jan;160(1):13-23 PMID: 12505794
  29. Enhanced amphetamine sensitivity and increased expression of dopamine D2 receptors in postpubertal rats after neonatal excitotoxic lesions of the medial prefrontal cortex.
    J Neurosci. 1996 Nov 15;16(22):7366-75 PMID: 8929443
  30. Progressive increase in striatal dopamine synthesis capacity as patients develop psychosis: a PET study.
    Mol Psychiatry. 2011 Sep;16(9):885-6 PMID: 21358709
  31. Cortical and subcortical 5-HT2A receptor binding in neuroleptic-naive first-episode schizophrenic patients.
    Neuropsychopharmacology. 2008 Sep;33(10):2435-41 PMID: 18288096
  32. Psychosis pathways converge via D2high dopamine receptors.
    Synapse. 2006 Sep 15;60(4):319-46 PMID: 16786561
  33. Neuroinflammation in schizophrenia-related psychosis: a PET study.
    J Nucl Med. 2009 Nov;50(11):1801-7 PMID: 19837763
  34. Decreased prefrontal dopamine D1 receptors in schizophrenia revealed by PET.
    Nature. 1997 Feb 13;385(6617):634-6 PMID: 9024661
  35. Serotonin 1A receptor availability in patients with schizophrenia and schizo-affective disorder: a positron emission tomography imaging study with [11C]WAY 100635.
    Psychopharmacology (Berl). 2006 Dec;189(2):155-64 PMID: 16953380
  36. Elevated striatal dopamine function linked to prodromal signs of schizophrenia.
    Arch Gen Psychiatry. 2009 Jan;66(1):13-20 PMID: 19124684
  37. Clinical studies on the mechanism of action of clozapine: the dopamine-serotonin hypothesis of schizophrenia.
    Psychopharmacology (Berl). 1989;99 Suppl:S18-27 PMID: 2682729
  38. Functional neuroimaging in schizophrenia: diagnosis and drug discovery.
    Trends Pharmacol Sci. 2008 Feb;29(2):91-8 PMID: 18187211
  39. Serotonin 5-HT2 receptors in schizophrenia: a PET study using [18F]setoperone in neuroleptic-naive patients and normal subjects.
    Am J Psychiatry. 1999 Jan;156(1):72-8 PMID: 9892300
  40. Molecular imaging studies of the striatal dopaminergic system in psychosis and predictions for the prodromal phase of psychosis.
    Br J Psychiatry Suppl. 2007 Dec;51:s13-8 PMID: 18055930
  41. Decreased serotonin 2A receptor densities in neuroleptic-naive patients with schizophrenia: A PET study using [(18)F]setoperone.
    Am J Psychiatry. 2000 Jun;157(6):1016-8 PMID: 10831488
  42. D(1) receptors in prefrontal cells and circuits.
    Brain Res Brain Res Rev. 2000 Mar;31(2-3):295-301 PMID: 10719156
  43. The dopaminergic basis of human behaviors: A review of molecular imaging studies.
    Neurosci Biobehav Rev. 2009 Jul;33(7):1109-32 PMID: 19481108
  44. Regional and cellular fractionation of working memory.
    Proc Natl Acad Sci U S A. 1996 Nov 26;93(24):13473-80 PMID: 8942959
  45. From dopamine to salience to psychosis--linking biology, pharmacology and phenomenology of psychosis.
    Schizophr Res. 2005 Nov 1;79(1):59-68 PMID: 16005191
  46. Reduced prefrontal activity predicts exaggerated striatal dopaminergic function in schizophrenia.
    Nat Neurosci. 2002 Mar;5(3):267-71 PMID: 11865311
  47. Impaired learning in a spatial working memory version and in a cued version of the water maze in rats with MPTP-induced mesencephalic dopaminergic lesions.
    Brain Res Bull. 2002 May;58(1):41-7 PMID: 12121811
  48. The dopamine hypothesis of schizophrenia: focus on the dopamine receptor.
    Am J Psychiatry. 1976 Feb;133(2):197-202 PMID: 1251927
  49. Neuroimaging studies of working memory: a meta-analysis.
    Cogn Affect Behav Neurosci. 2003 Dec;3(4):255-74 PMID: 15040547
  50. A systematic review of the prevalence of schizophrenia.
    PLoS Med. 2005 May;2(5):e141 PMID: 15916472
  51. An antiserotonin which is active when fed.
    J Pharmacol Exp Ther. 1953 May;108(1):87-93 PMID: 13053426
  52. PET study of D(1) dopamine receptor binding in neuroleptic-naive patients with schizophrenia.
    Am J Psychiatry. 2002 May;159(5):761-7 PMID: 11986129
  53. Serotonin model of schizophrenia: emerging role of glutamate mechanisms.
    Brain Res Brain Res Rev. 2000 Mar;31(2-3):302-12 PMID: 10719157
  54. Monoamine neuron innervation of the normal human brain: an 18F-DOPA PET study.
    Brain Res. 2003 Aug 29;982(2):137-45 PMID: 12915249
  55. Dopamine receptors in the brains of schizophrenia patients: a meta-analysis of the findings.
    Behav Pharmacol. 2001 Sep;12(5):355-71 PMID: 11710751
  56. 5-HT2A receptor density is decreased in the at-risk mental state.
    Psychopharmacology (Berl). 2008 Jan;195(4):579-90 PMID: 17899021
  57. Pathways to schizophrenia: the impact of environmental factors.
    Int J Neuropsychopharmacol. 2004 Mar;7 Suppl 1:S7-S13 PMID: 14972079
  58. Towards NR2B receptor selective imaging agents for PET-synthesis and evaluation of N-[11C]-(2-methoxy)benzyl (E)-styrene-, 2-naphthyl- and 4-trifluoromethoxyphenylamidine.
    Bioorg Med Chem. 2006 Sep 15;14(18):6307-13 PMID: 16777419
  59. Abnormal frontostriatal interactions in people with prodromal signs of psychosis: a multimodal imaging study.
    Arch Gen Psychiatry. 2010 Jul;67(7):683-91 PMID: 20603449
  60. Molecular, pharmacological and functional diversity of 5-HT receptors.
    Pharmacol Biochem Behav. 2002 Apr;71(4):533-54 PMID: 11888546
  61. Brain serotonin 5-HT(1A) receptor binding in schizophrenia measured by positron emission tomography and [11C]WAY-100635.
    Arch Gen Psychiatry. 2002 Jun;59(6):514-20 PMID: 12044193
  62. The relationship between dorsolateral prefrontal neuronal N-acetylaspartate and evoked release of striatal dopamine in schizophrenia.
    Neuropsychopharmacology. 2000 Feb;22(2):125-32 PMID: 10649825
  63. Antagonism between lysergic acid diethylamide and 5-hydroxytryptamine.
    J Physiol. 1953 Jul;121(1):15P PMID: 13085323
  64. Schizophrenia.
    Lancet. 1999 Apr 24;353(9162):1425-30 PMID: 10227239
  65. Decreased frontal serotonin2A receptor binding in antipsychotic-naive patients with first-episode schizophrenia.
    Arch Gen Psychiatry. 2010 Jan;67(1):9-16 PMID: 20048218
  66. Pathophysiologically based treatment interventions in schizophrenia.
    Nat Med. 2006 Sep;12(9):1016-22 PMID: 16960576
  67. Prepsychotic phase of schizophrenia and related disorders: recent progress and future opportunities.
    Br J Psychiatry Suppl. 2005 Aug;48:s33-44 PMID: 16055805
  68. Neuropsychological deficits in individuals with an at risk mental state for psychosis - working memory as a potential trait marker.
    Schizophr Res. 2007 Dec;97(1-3):14-24 PMID: 17936587
  69. Working memory and dopamine: clinical and experimental clues.
    Curr Opin Neurol. 2003 Dec;16 Suppl 2:S29-35 PMID: 15129848
  70. Mechanisms underlying psychosis and antipsychotic treatment response in schizophrenia: insights from PET and SPECT imaging.
    Curr Pharm Des. 2009;15(22):2550-9 PMID: 19689327
  71. The dopamine D2 receptors in high-affinity state and D3 receptors in schizophrenia: a clinical [11C]-(+)-PHNO PET study.
    Neuropsychopharmacology. 2009 Mar;34(4):1078-86 PMID: 18987627
  72. Cognitive functioning in the schizophrenia prodrome.
    Schizophr Bull. 2007 May;33(3):761-71 PMID: 17412711
  73. Neonatal medial prefrontal cortex lesion enhances the sensitivity of the mesoaccumbal dopamine system.
    Eur J Neurosci. 2004 Jun;19(12):3277-90 PMID: 15217384
  74. Therapeutic signposts: using biomarkers to guide better treatment of schizophrenia and other psychotic disorders.
    Med J Aust. 2009 Feb 16;190(S4):S26-32 PMID: 19220170
  75. Imaging dopamine transmission in schizophrenia. A review and meta-analysis.
    Q J Nucl Med. 1998 Sep;42(3):211-21 PMID: 9796369
  76. Perspectives: an international review of the national cost estimates of mental illness, 1990-2003.
    J Ment Health Policy Econ. 2006 Mar;9(1):3-13 PMID: 16733267
  77. Increased baseline occupancy of D2 receptors by dopamine in schizophrenia.
    Proc Natl Acad Sci U S A. 2000 Jul 5;97(14):8104-9 PMID: 10884434
  78. Under the curve: critical issues for elucidating D1 receptor function in working memory.
    Neuroscience. 2006 Apr 28;139(1):263-76 PMID: 16310964
  79. Serotonin transporter availability in patients with schizophrenia: a positron emission tomography imaging study with [11C]DASB.
    Biol Psychiatry. 2005 Jun 15;57(12):1510-6 PMID: 15953487
  80. Increased synaptic dopamine function in associative regions of the striatum in schizophrenia.
    Arch Gen Psychiatry. 2010 Mar;67(3):231-9 PMID: 20194823
  81. Microglia dysfunction in schizophrenia: an integrative theory.
    Med Hypotheses. 2000 Feb;54(2):198-202 PMID: 10790752
  82. N-back working memory paradigm: a meta-analysis of normative functional neuroimaging studies.
    Hum Brain Mapp. 2005 May;25(1):46-59 PMID: 15846822
  83. Dopamine and serotonin transporters in patients with schizophrenia: an imaging study with [(123)I]beta-CIT.
    Biol Psychiatry. 2000 Mar 1;47(5):371-9 PMID: 10704949
  84. Beyond hypofrontality: a quantitative meta-analysis of functional neuroimaging studies of working memory in schizophrenia.
    Hum Brain Mapp. 2005 May;25(1):60-9 PMID: 15846819
  85. The distribution of substance P and 5-hydroxytryptamine in the central nervous system of the dog.
    J Physiol. 1954 Dec 10;126(3):596-618 PMID: 13222357
  86. No serotonin 5-HT2A receptor density abnormality in the cortex of schizophrenic patients studied with PET.
    Schizophr Res. 1998 May 4;31(1):13-7 PMID: 9633832
  87. Increased striatal dopamine transmission in schizophrenia: confirmation in a second cohort.
    Am J Psychiatry. 1998 Jun;155(6):761-7 PMID: 9619147
  88. A positron emission tomography study of the 5-HT1A receptor in schizophrenia and during clozapine treatment.
    J Psychopharmacol. 2004 Sep;18(3):346-54 PMID: 15358978
  89. Cost of schizophrenia to UK Society. An incidence-based cost-of-illness model for the first 5 years following diagnosis.
    Pharmacoeconomics. 1999 Jun;15(6):597-610 PMID: 10538332
  90. Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects.
    Proc Natl Acad Sci U S A. 1996 Aug 20;93(17):9235-40 PMID: 8799184
  91. What causes the onset of psychosis?
    Schizophr Res. 2005 Nov 1;79(1):23-34 PMID: 16198238
  92. Abnormal P300 in people with high risk of developing psychosis.
    Neuroimage. 2008 Jun;41(2):553-60 PMID: 18387827
  93. Dopamine synthesis capacity before onset of psychosis: a prospective [18F]-DOPA PET imaging study.
    Am J Psychiatry. 2011 Dec;168(12):1311-7 PMID: 21768612
  94. Neurocognitive indicators for a conversion to psychosis: comparison of patients in a potentially initial prodromal state who did or did not convert to a psychosis.
    Schizophr Res. 2007 May;92(1-3):116-25 PMID: 17344028
  95. Dopaminergic modulation of visual-spatial working memory in Parkinson's disease.
    Dement Geriatr Cogn Disord. 2003;15(2):55-66 PMID: 12566593
Article Info
Journal
Current pharmaceutical design
Abbr.
Curr Pharm Des
ISSN
1873-4286
Published
2012-00-00
Pages
459-65
Language
English
Region
United Arab Emirates
NLM ID
9602487
PMCID
PMC3662992
Subset
IM
Grants
Medical Research Council · G0700995 · United Kingdom
Medical Research Council · MC_U120097115 · United Kingdom
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com